Should You Obtain Bone Density Before Prescribing Alendronate in a 67-Year-Old?
Yes, you should obtain a DXA bone density measurement before prescribing alendronate in a 67-year-old patient. This is the standard of care supported by current guidelines, FDA labeling, and clinical practice.
Rationale for DXA Before Treatment
Guideline-Based Approach
The 2025 USPSTF guidelines recommend screening all women aged 65 years and older with DXA to identify osteoporosis and guide treatment decisions 1. At age 67, your patient falls squarely within this recommendation. DXA is the gold standard for diagnosing osteoporosis because it correlates with bone strength, predicts fracture risk, and was the test used in virtually all clinical trials that established alendronate's efficacy 1.
FDA Label Requirements
The FDA approval of alendronate was based on studies that enrolled patients with documented osteoporosis defined by specific DXA criteria 2. The pivotal Fracture Intervention Trials required:
- Lumbar spine BMD at least 2 standard deviations below the premenopausal mean, OR
- Femoral neck T-score ≤ -2.5
Without baseline DXA, you cannot confirm your patient meets the diagnostic criteria for osteoporosis that justified alendronate approval and demonstrated fracture reduction.
Clinical Practice Standards
The 2019 Endocrine Society guidelines suggest monitoring BMD by DXA every 1-3 years during treatment to assess response 3. You cannot monitor treatment response without a baseline measurement. Establishing baseline BMD allows you to:
- Confirm the diagnosis of osteoporosis (T-score ≤ -2.5)
- Quantify fracture risk
- Track treatment efficacy over time
- Identify treatment failure or non-adherence
Specific DXA Protocol
Order DXA of the lumbar spine and bilateral proximal femurs 1, 4. This dual-site approach is standard because:
- Hip BMD predicts hip fracture more strongly than other sites 5
- Lumbar spine measurements may be artifactually elevated in older patients due to degenerative changes
- Having both sites provides backup if one is uninterpretable
Common Pitfalls to Avoid
Do not prescribe alendronate empirically without DXA, even if the patient has risk factors. While the patient's age (67) places her at higher risk, approximately 31% of women in this age range do not meet osteoporosis criteria 2. Treating without confirmation exposes patients to potential bisphosphonate risks (rare atypical femoral fractures, osteonecrosis of the jaw) without documented benefit.
Do not rely on plain radiographs alone. Standard X-rays cannot detect osteoporosis until 30-40% of bone mass is lost and should only supplement DXA when there's a specific indication 6.
Treatment Decision Algorithm
Order DXA of lumbar spine and bilateral hips
Interpret T-scores:
- T-score ≤ -2.5 at any site = Osteoporosis → Alendronate indicated
- T-score -1.0 to -2.5 = Osteopenia → Consider FRAX score and clinical risk factors
- T-score > -1.0 = Normal → Alendronate not indicated
If osteoporosis confirmed, prescribe alendronate 70 mg weekly 2
Repeat DXA in 1-3 years to monitor treatment response 3
The evidence consistently demonstrates that alendronate reduces vertebral fractures by 45-48% and hip fractures in women with documented osteoporosis 2, 7. However, this benefit was established in populations selected by DXA criteria, making baseline bone density measurement an essential prerequisite for appropriate prescribing.